CoChat
Sign Up
Cited by 317Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Activation of PPARδ alters lipid metabolism in db/db mice

Open access
Leibowitz, Mark D., Fiévet, Catherine, Hennuyer, Nathalie, Peinado-Onsurbe, Julia, Duez, Hélène, Berger, Joel, Cullinan, Catherine A., Sparrow, Carl P., Baffic, Joanne, Berger, Gregory D., Santini, Conrad, Marquis, Robert W., Tolman, Richard L., Smith, Roy G., Moller, David E., Auwerx, Johan·2000·FEBS Letters
DOI 10.1016/s0014-5793(00)01554-4
Open this paper in CoChat — free accountOpen PDF

Abstract

Peroxisome proliferator‐activated receptors (PPARs) are nuclear receptors, which heterodimerize with the retinoid X receptor and bind to peroxisome proliferator response elements in the promoters of regulated genes. Despite the wealth of information available on the function of PPARα and PPARγ, relatively little is known about the most widely expressed PPAR subtype, PPARδ. Here we show that treatment of insulin resistant db/db mice with the PPARδ agonist L‐165 041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. The increased cholesterol was primarily associated with high density lipoprotein (HDL) particles, as shown by fast protein liquid chromatography analysis. These data were corroborated by the chemical analysis of the lipoproteins isolated by ultracentrifugation, demonstrating that treatment with L‐165 041 produced an increase in circulating HDL without major changes in very low or low density lipoproteins. White adipose tissue lipoprotein lipase activity was reduced following treatment with the PPARδ ligand, but was increased by a PPARγ agonist. These data suggest both that PPARδ is involved in the regulation of cholesterol metabolism in db/db mice and that PPARδ ligands could potentially have therapeutic value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0014-5793(00)01554-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. 10.1210/en.137.10.4189 · DOI · Paper page
  2. 10.1210/me.6.10.1634 · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., Santini, C., Marquis, R. W., Tolman, R. L., Smith, R. G., Moller, D. E., & Auwerx, J.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Inserm (FR)
Corresponding author
Leibowitz, Mark D.
ORCID
Venue
FEBS Letters
Publisher
Wiley
Published
2000-05-12
Volume
473
Issue
3
Pages
333-336
ISSN
  • 0014-5793 (ISSN-L)
  • 1873-3468
DOI
10.1016/s0014-5793(00)01554-4
OpenAlex
W2024254257
Cited by
308
References
26
Citations by year
2025: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 9 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 7 · 2013: 13 · 2012: 8
FWCI
7.23
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • FEBS Letters (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
PPARδ, db/db mice, type 2 diabetes, insulin resistance, HDL cholesterol, serum cholesterol, lipoprotein lipase, white adipose tissue, PPARγ agonists, lipid metabolism, nuclear receptors
MeSH terms
Acetates, Adipose Tissue, Animals, Blood Glucose, Cholesterol, Chromatography, Liquid, DNA-Binding Proteins, Ligands, Lipids, Lipoprotein Lipase, Lipoproteins, Male, Mice, Inbred C57BL, Mice, Mutant Strains, Phenols, Phenoxyacetates, Transcription Factors, Triglycerides, Ultracentrifugation, Receptors, Cytoplasmic and Nuclear, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review